A look at ROVA-T's chances in the upcoming phase 2 TRINITY trial readout
A look at the trials and tribulations for Immune Design's CMB305 and what's the latest in 1L NSCLC
A look at the FDA briefing docs on Puma's neratinib
We've been overdue a correction in the irrational exuberance around IO... is this the tip of the iceberg?
BSB Reader Mailbag on TRK/ROS1/ALK inhibitors
Latest BSB reader Q&A looks at 5 questions from subscribers
Reader Q&A on women's cancers relating to HER2, PARP and TNBC...
A look at the how several major phase 3 trial readouts will affect the 1L NSCLC landscape
Latest BSB mailbag covers targeted therapies, immunotherapy and #ESMO16
July Reader Q&A - thoughts on Jounce, Celgene, BMS, J&J and CAR T cell therapies...
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news
Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies
This month's Biotech Strategy Blog mail bag.
Insights on targeted therapies from ASCO - questions from subs on neratinib, bavituximab, enzalutamide, Gilead's pipeline and MDSCs...